Evelo partners with Univ. of Chicago, options gut microbe immunotherapy; therapy licensed
The University of Chicago granted Evelo Therapeutics an option to exclusively license global rights to a microbiome-based immunotherapy developed by the university's Thomas Gajewski, MD, PhD.
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.